Navigation Links
Romark Announces Clinical Trial Results for New Influenza Drug Presented at IDSA Meeting 2011
Date:10/21/2011

se group and 116.7 hours for patients receiving the placebo. Time to resolution of symptoms for the low dose group were less than for the placebo, but the difference was not statistically significant (P=0.521). Patients in the 600 mg NTZ treatment group also experienced statistically significant reductions in quantitative viral shedding compared to patients receiving the placebo (P=0.0006). Adverse events were similar for the three treatment groups except for a higher rate of mild diarrhea in the 600 mg treatment group (8.1%) compared to the placebo treatment group (3.3%).

About the Phase 2 Clinical Trials

Two Phase 2 clinical trials, one in pediatric patients age 1 to 11 years, and another in adults and adolescents age 12 – 65 years, were conducted at a single center in Cajamarca, Peru.  Patients were enrolled based upon symptoms consistent with influenza (fever, at least one respiratory symptom and one constitutional symptom) and randomly assigned to receive treatment with NTZ or placebo in double-blind fashion.  Patients in the pediatric study received 100 mg NTZ (age 12 – 47 months), 200 mg NTZ (age 4 – 11 years) or placebo twice daily for five days as an oral suspension.  Patients enrolled in the study of adults and adolescents received 500 mg NTZ or placebo twice daily for five days as an oral tablet.  Identification of respiratory viruses at baseline was performed by ELISA.  Patients were visited daily by a study nurse to monitor the health of the patients, ensure compliance with the study medication and recording of symptoms in a patient diary, and to collect tissue with nasal secretions, and patients were followed up at study day 7.  The primary efficacy endpoint was time from first dose to alleviation of symptoms (all symptoms absent or mild and remained so for 24 hours).  

One-hundred children, median age 3 years, were enrolled in the pediatric trial (50 per tre
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Raises $18 Million in Institutional Financing
3. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
4. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
5. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
6. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
7. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
8. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
9. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
10. Romark Announces Data Presented at AASLD Meeting 2010
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 2015  IRIDEX Corporation (Nasdaq: IRIX ) today ... granted the Company a patent for a new proprietary ... eye surgery. The iClip Closure Device will initially be ... a broader range of ophthalmic surgical procedures in the ... procedure used in the treatment of glaucoma to drain ...
(Date:3/29/2015)... , March 29, 2015  Three-month paliperidone palmitate, ... relapse compared to placebo in patients with schizophrenia, ... published this week in the Journal ... . Results of the study served ... Application (NDA) filing for three-month paliperidone palmitate injection ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 ... of Ohr Pharmaceutical, Inc. (NASDAQ: OHRP ) concerning ... certain statements issued by the Company in connection with ... information, GO TO: http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact ... jlevi@zlk.com or by telephone at (212) 363-7500, ...
Breaking Medicine Technology:IRIDEX Granted U.S. Patent for Disposable Device for Efficient and Predictable Wound Closure in Eye Surgeries 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12
(Date:3/30/2015)... Jose, California (PRWEB) March 30, 2015 ... Defined as radioactive isotopes, radiopharmaceuticals are used as ... The global market for radiopharmaceuticals is driven by ... procedures in the field of cardiology, neurology, pulmonology, ... supported by the well-established use of radioisotopes in ...
(Date:3/30/2015)... Daily sun exposure, stressors and environmental factors ... folds and other giveaways of age. However, advances in ... to hit the pause button, delaying the impact of ... or hack to rejuvenate any facial feature. , ... (AAFPRS) explores the intricacies of The Aging Face ...
(Date:3/30/2015)... Mid-America ATTC has just released ... used in behavioral health and addiction treatment. , ... a convenient, electronic version of the helpful reference ... resource provides up-to-date information on generic and brand ... effects, emergency conditions, cautions, considerations for pregnant women, ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 ... recognized designer and manufacturer of ergonomic seating ... upholstery options. The new upholsteries bolster the ... and custom seating, providing disinfectable, green choices. ... by renowned textile purveyor CF Stinson. Six ...
(Date:3/29/2015)... March 30, 2015 At the 2015 ... Helo Commercial introduced the new Fonda wall mounted ... , Club owners and facilities managers with saunas ... new, sleek design of the Fonda heater. With ... heater is an immediate upgrade for a sauna, especially ...
Breaking Medicine News(10 mins):Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 2Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 3Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 4Health News:New AAFPRS Infographic Addresses Concerns and Provides Aging Face Solutions 2Health News:Popular Publication on Behavioral Health Medications Now An App 2Health News:BioFit Adds Bleachable Upholstery Options to Seating Line 2Health News:Helo Commercial Introduces Fonda Sauna Heater and Sauna and Steam Continuing Education Program at IHRSA 2
... , , , , ... 21 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today reported ... total revenue of $209.4 million for the quarter ended June 30, 2009, ... charge of $11.4 million associated with the Company,s sales force reduction in ...
... , , ALISO VIEJO, Calif., July ... that it will host a conference call and a live Internet webcast ... a.m. EDT (7:00 a.m. PDT) to discuss results for the 2009 second ... participate on this call is (877) 295-5743, confirmation code 20797641. International ...
... First three cases of likely HIV transmission to infants ... against pre - chewing food; also a ... Tenn., July 21 Researchers have uncovered the first cases in ... through pre-chewed food. The source of HIV in the pre-chewed food was most ...
... , SALT LAKE CITY, July 21 Health ... its innovative features, most notably its ability to save exercise data ... account to track progress. The LifeSpan TR4000i treadmill, made by PCE ... as judged by experts from Health magazine. The Best Treadmill award ...
... American men could be putting their health at risk ... results might threaten their masculinity. Because they prove their ... advice including HIV/AIDS testing goes against their notion of ... Department of Sociology at Yale University in the US, ...
... , NEW YORK, July 21 ... research teams at nine biotech and pharmaceutical companies a total ... investigations aim to push forward novel neuroprotective and improved symptomatic ... treatment. , , While MJFF ...
Cached Medicine News:Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 2Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 3Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 4Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 5Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 6Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 7Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 8Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 9Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 10Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 11Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 12Health News:Valeant Pharmaceuticals to Announce 2009 Second Quarter Results on August 4, 2009 2Health News:Pre-chewed Food Could Transmit HIV 2Health News:Pre-chewed Food Could Transmit HIV 3Health News:Pre-chewed Food Could Transmit HIV 4Health News:LifeSpan Treadmill Awarded BEST TREADMILL by Health Magazine 2Health News:'Go to the doctor? Only if I'm really sick ...' 2Health News:Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinson's Drug Development 2Health News:Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinson's Drug Development 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: